CompletedNot Applicable

Axillary Reverse Mapping in Breast Cancer

Spain43 participantsStarted 2021-06-01

Plain-language summary

The axillary mapping reverse (ARM) consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema. A significant decrease of lymphedema rates in patients who was possible associate ARM technique during the axillary surgery improving the quality of life of these patients. There are different visualisation techniques like fluorescence dye.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients who will undergo ALND in the treatment of breast cancer: * cT4a, cT4c and cT4d. * cT4b with extensive involvement of the skin. * cN0 with SLNB positive (pN+) that need to associate ALND: * cT3-T4b. * \>2 lymph node macrometastasis if cTis, cT1 and cT2. * Patients who underwent mastectomy and it is not possible associate adjuvant radiotherapy. * cN1: * If primary surgery treatment. * After neoadjuvant systemic treatment, if there is not a clinical-radiological complete response and/or SLNB positive (ypN+). * cN2: * If primary surgery treatment. * After neoadjuvant systemic treatment, if luminal tumours or there is not a clinical-radiological complete response in triple negative or HER2 overexpressed tumours. * cN3. Exclusion Criteria: * Patients with previous axillary surgery (except sentinel node biopsy) * Patients who did previous axillary radiotherapy treatment. * Patients who do not wish to participate in the study.

What they're measuring

Rate of patients who it is possible preserve ARM nodes

Timeframe: 1 year

Trial details

NCT IDNCT05040685

SponsorHospital Universitari de Bellvitge

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-01